Spero Therapeutics (SPRO) Revenue Growth (3y) (2019 - 2026)
Spero Therapeutics (SPRO) Revenue Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 77.85% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -25.02% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 42.02% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 59.40% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -37.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 76.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.80% |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.04% |
| Dec 31, 2025 | -9.13% |
| Mar 31, 2025 | -63.51% |
| Dec 31, 2024 | 26.08% |
| Sep 30, 2024 | -54.89% |
| Jun 30, 2024 | 25.59% |
| Mar 31, 2024 | -73.23% |
| Sep 30, 2023 | 775.18% |
| Jun 30, 2023 | 276.23% |
| Mar 31, 2023 | -49.20% |
| Dec 31, 2022 | 188.86% |
| Sep 30, 2022 | 84.60% |
| Jun 30, 2022 | 137.36% |
| Mar 31, 2022 | -68.25% |
| Dec 31, 2021 | -110.70% |
| Sep 30, 2021 | 2.47% |
| Jun 30, 2021 | 123.20% |
| Sep 30, 2020 | -60.07% |
| Jun 30, 2020 | -41.05% |
| Mar 31, 2020 | 129.89% |